Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

New England Journal of Medicine

Volumn 345, Issue 13, 2001, Pages 948-955

  Smith, Matthew R ^a   McGovern, Francis J ^a   Zietman, Anthony L ^a   Fallon, Mary Anne ^a   Hayden, Douglas L ^a   Schoenfeld, David A ^a   Kantoff, Philip W ^b   Finkelstein, Joel S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; GONADORELIN AGONIST; LEUPRORELIN; PAMIDRONIC ACID;

ADULT; AGED; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MINERAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR; FRACTURE; HIP; HUMAN; LUMBAR SPINE; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TRABECULAR BONE;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BONE DENSITY; BONE RESORPTION; DIPHOSPHONATES; FEMUR; GONADOTROPIN-RELEASING HORMONE; HUMANS; LEUPROLIDE; LUMBAR VERTEBRAE; MALE; OSTEOCALCIN; OSTEOPOROSIS; PELVIC BONES; PROSTATIC NEOPLASMS;

EID: 0035960116     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa010845     Document Type: Article

References (29)

1. Cancer statistics, 2001
2. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial
3. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
4. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer
5. Progressive osteoporosis during androgen deprivation therapy for prostate cancer
6. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: Longitudinal evaluation and response to intermittent cyclic etidronate therapy
7. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma
8. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens
9. Osteoporosis after orchiectomy for prostate cancer
10. Bone fractures associated with luteinizing hormone-releasing agonists used in the treatment of prostate carcinoma
11. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer
12. Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause
13. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: A randomized trial
14. Appendicular bone density and age predict hip fracture in women
15. Effect ofalendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
16. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial
17. Effect of testosterone treatment on bone mineral density in men over 65 years of age
18. Alendronate for the treatment of osteoporosis in men
19. Androgens and bone metabolism
20. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism
21. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men: A clinical research center study
22. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism
23. Posterior-anterior and lateral dual-energy x-ray absorptiometry for the assessment of vertebral osteoporosis and bone loss among older men
24. The impact of osteophytic and vascular calcifications on vertebral mineral density measurements in men
25. Radiologic diagnosis of osteoporosis: Current methods and perspectives
26. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis
27. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: A prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone